FibroBiologics Files Patent Application for Oral Administration of Fibroblast Therapeutics

FibroBiologics (Nasdaq:FBLG) filed a new provisional patent application with the USPTO for oral fibroblast and fibroblast-derived therapeutics.

Rhea-AI Summary

FibroBiologics (Nasdaq:FBLG) filed a new provisional patent application with the USPTO for oral fibroblast and fibroblast-derived therapeutics. The platform targets delivery to the gastrointestinal tract using encapsulation materials, hydrogels, nanoparticles, protective layers, and pH-sensitive coatings to preserve viability and enable targeted release.

The application covers whole fibroblast cells, spheroids, extracellular vesicles, fragments, conditioned media, and genetically modified variants, with potential use in chronic GI disorders such as inflammatory bowel disease, irritable bowel syndrome, Crohn's disease, ulcerative colitis, peptic ulcer disease, celiac disease, gastritis, and gastrointestinal cancers.

Argus May 18 session

+3.81% close to close Open Argus

Details

News Market Reaction – FBLG

On May 18, the day this news came out, FBLG closed 3.81% above the previous close.

Data tracked by StockTitan Argus for the May 18 session.

Key Figures

Patent estate: 270+ patents ATM capacity: $7,500,000 ATM prior 12M sales: $8.14 million +5 more

Patent estate

270+ patents

Issued and pending across fibroblast therapeutics platform

ATM capacity

$7,500,000

Maximum common stock sales under updated ATM facility

ATM prior 12M sales

$8.14 million

Common stock sold in 12 months before May 5, 2026

Earlier supplement sales

$0.17 million

Common stock sold under prior ATM supplement

Public float

$47.0 million

Based on 5,399,112 non‑affiliate shares as of May 5, 2026

Non‑affiliate shares

5,399,112 shares

Used in public float calculation as of May 5, 2026

Reverse split ratio

1-for-20

Reverse stock split effective March 30, 2026

New ATM offering size

$6,150,000

Common stock in at‑the‑market offering under Sales Agreement

Historical Context

5 past events · Latest: May 11

5 events

1. May 11

   Pipeline expansion

   24h Move

   -14.7%

   Expanded fibroblast platform into Hantavirus pulmonary syndrome preclinical work.

2. May 05

   Shareholder letter

   24h Move

   -3.6%

   Outlined CYWC628 trial start, timelines, and broader preclinical program plans.

3. May 04

   Preclinical data

   24h Move

   -3.6%

   Reported burn-wound fibroblast spheroid data with anti-inflammatory biomarker shifts.

4. May 04

   Clinical supply ready

   24h Move

   -5.5%

   Released first cGMP CYWC628 batch enabling Phase 1/2 DFU trial enrollment.

5. Apr 30

   Earnings update

   24h Move

   +10.6%

   Q1 2026 results with CYWC628 manufacturing progress and capital raise details.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

provisional patent application, u.s. patent and trademark office, extracellular vesicles, enteric coatings, +4 more

8 terms

provisional patent application regulatory

"today announced the filing of a new provisional patent application with the U.S."

A provisional patent application is a lightweight, temporary filing that records an inventor’s idea and sets an official filing date without starting the full patent review process. Think of it as placing a hold on an idea while you prepare the complete paperwork; it doesn’t grant a patent but can preserve the right to seek one later. For investors, it signals a company is protecting potential intellectual property, which can affect future competitive advantage and valuation, but it is not a guarantee of patent protection.

u.s. patent and trademark office regulatory

"application with the U.S. Patent and Trademark Office (USPTO) titled"

The U.S. Patent and Trademark Office is the federal agency that reviews and grants patents and registers trademarks, like a land office that issues official property deeds for inventions and brand names. For investors, its decisions matter because patents and trademarks can create legal protection and exclusive market rights that boost a company’s revenue potential, reduce competition, and change risk and valuation dynamics.

extracellular vesicles medical

"including whole cells, spheroids, extracellular vesicles, fragments, conditioned media"

Extracellular vesicles are tiny, cell-made particles—think microscopic bubbles—that carry proteins, genetic material and signals between cells. Investors care because these vesicles can be used as disease markers, drug-delivery vehicles, or therapeutic products; that creates opportunities and risks around clinical validation, manufacturing scale-up, intellectual property and regulatory approval that can materially affect the value of biotech and diagnostics companies.

enteric coatings medical

"using encapsulation materials and enteric coatings engineered to preserve viability"

A thin, specially formulated layer applied to pills or capsules that keeps the medicine from dissolving in the stomach and releases it later in the intestines; think of it like a time-release wrapper that protects a product until it reaches the right environment. For investors, enteric coatings affect a drug’s effectiveness, side-effect profile, manufacturing cost, regulatory approval path, patentability and market differentiation, all of which can influence sales and risk.

hydrogels medical

"platform contemplates multilayer delivery architectures incorporating hydrogels, nanoparticles"

Hydrogels are soft, jelly-like materials made from long chains of molecules that trap and hold large amounts of water, similar to a sponge that stays intact when wet. They matter to investors because they are used in many medical and consumer products — such as drug delivery patches, wound dressings, contact lenses and tissue scaffolds — and changes in their performance, cost or regulatory approval can directly affect a company’s product value and market potential.

nanoparticles technical

"delivery architectures incorporating hydrogels, nanoparticles, protective intermediate layers"

Extremely tiny bits of matter, measured in billionths of a meter, that can behave differently from the same material at larger sizes. Think of them as microscopic delivery trucks or building blocks that can carry drugs to specific cells, boost material strength, or enable new electronic features. Investors care because nanoparticle use can change a product’s effectiveness, manufacturing complexity, regulatory scrutiny, patent value and cost profile, all of which affect a company’s future revenue and risk.

gastrointestinal tract medical

"deliver regenerative and immunomodulatory activity directly to the gastrointestinal tract."

The gastrointestinal tract is the continuous tube from the mouth to the anus that breaks down food, absorbs nutrients and expels waste — imagine a processing plant or conveyor belt for everything you eat. Investors care because many drugs, medical devices and diagnostics target this system; disorders or successful treatments can drive sales, affect clinical trial outcomes, change regulatory decisions and shift healthcare spending, all of which influence company value.

pH-sensitive technical

"protective intermediate layers, and pH-sensitive outer coatings designed to bypass"

pH-sensitive describes a material, drug formulation, or device that changes its behavior—such as dissolving, releasing a drug, swelling, or altering activity—when exposed to different acidity or alkalinity levels. For investors, pH sensitivity matters because it can improve targeted delivery or shelf life but also raises questions about manufacturing complexity, regulatory testing, and real-world reliability; think of it like a time-release capsule designed to open only in certain parts of the body.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

HOUSTON, May 18, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending focused on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced the filing of a new provisional patent application with the U.S. Patent and Trademark Office (USPTO) titled “Oral Fibroblasts and Fibroblast-Derived Therapeutics and Delivery Systems for Same” covering oral delivery systems designed to protect fibroblast-based therapeutics through the stomach and enable targeted release in the gastrointestinal tract.

The provisional patent application describes an oral administration platform intended to deliver fibroblasts and fibroblast-derived therapeutics, including whole cells, spheroids, extracellular vesicles, fragments, conditioned media, and genetically modified variants, to the GI tract using encapsulation materials and enteric coatings engineered to preserve viability and bioactivity during transit.

The disclosed platform contemplates multilayer delivery architectures incorporating hydrogels, nanoparticles, protective intermediate layers, and pH-sensitive outer coatings designed to bypass gastric acid and digestive enzymes before releasing therapeutic payloads in targeted regions of the intestine. The application describes potential oral administration modality across chronic gastrointestinal disorders including inflammatory bowel disease, irritable bowel syndrome, peptic ulcer disease, celiac disease, gastritis, Crohn's disease, ulcerative colitis, and gastrointestinal cancers.

Pete O'Heeron, Founder and Chief Executive Officer of FibroBiologics commented, "A successful oral fibroblast therapeutic could meaningfully change the treatment paradigm by offering a more accessible, non-invasive approach designed to deliver regenerative and immunomodulatory activity directly to the gastrointestinal tract. We believe this oral platform has the potential to open an entirely new frontier for fibroblast-based medicine."

"What makes this filing especially compelling is the breadth of the therapeutic architecture," said Hamid Khoja, Ph.D., Chief Scientific Officer of FibroBiologics. "The application covers not only fibroblasts, but also fibroblast-derived materials, engineered variants, multilayer encapsulation approaches, and programmable release concepts intended to maintain viability and function through oral delivery. From a scientific perspective, this gives us a versatile framework for exploring how fibroblast-based therapeutics may help restore barrier function, modulate inflammation, and support tissue repair in gastrointestinal disease settings."

For more information, please visit FibroBiologics' website, email FibroBiologics at info@fibrobiologics.com or follow FibroBiologics on LinkedIn, YouTube, Facebook or X.

About FibroBiologics
Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and seeking potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 270+ US and internationally issued patents/patents pending across various clinical pathways, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy and tissue regeneration. For more information, visit www.FibroBiologics.com.

Cautionary Statement Regarding Forward-Looking Statements
This communication contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding the scope and strength of the Company’s intellectual property portfolio, the potential of FibroBiologics’ novel fibroblast technology, and the potential indications for FibroBiologics’ programs. These forward-looking statements are based on FibroBiologics’ management’s current expectations, estimates, projections, and beliefs, as well as a number of assumptions concerning future events. When used in this communication, the words “estimates,” “projected,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside FibroBiologics’ management’s control, that could cause actual results to differ materially from the results discussed in the forward-looking statements, including those set forth under the caption “Risk Factors” and elsewhere in FibroBiologics’ annual, quarterly and current reports (i.e., Form 10-K, Form 10-Q and Form 8-K) as filed or furnished with the SEC and any subsequent public filings. Copies are available on the SEC’s website, www.sec.gov. These risks, uncertainties, assumptions and other important factors include, but are not limited to: (a) risks related to FibroBiologics’ liquidity and its ability to maintain capital resources sufficient to conduct its business; (b) expectations regarding the initiation, progress and expected results of FibroBiologics’ R&D efforts and preclinical studies; (c) the unpredictable relationship between R&D and preclinical results and clinical study results; and (d) the ability of FibroBiologics to successfully prosecute its patent applications. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and FibroBiologics assumes no obligation and, except as required by law, does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. FibroBiologics gives no assurance that it will achieve its expectations.

General Inquiries:
info@fibrobiologics.com

Investor Relations:
Nic Johnson
Russo Partners
(212) 845-4242
fibrobiologicsIR@russopr.com

Media Contact:
Liz Phillips
Russo Partners
(347) 956-7697
Elizabeth.phillips@russopartnersllc.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did FibroBiologics (Nasdaq:FBLG) announce on May 18, 2026 about oral fibroblast therapeutics?

FibroBiologics announced a new provisional patent filing for oral fibroblast and fibroblast-derived therapeutics. According to FibroBiologics, the patent covers delivery systems that protect these therapeutics through the stomach and enable targeted release in the gastrointestinal tract using encapsulation and enteric coating technologies.

How does FibroBiologics' new oral fibroblast delivery platform work for GI tract targeting (FBLG)?

The platform uses multilayer oral delivery architectures to protect fibroblast-based therapeutics during GI transit. According to FibroBiologics, it incorporates hydrogels, nanoparticles, protective intermediate layers, and pH-sensitive outer coatings to bypass gastric acid and digestive enzymes before releasing therapeutic payloads in specific intestinal regions.

Which gastrointestinal diseases could FibroBiologics' oral fibroblast therapeutics address for FBLG shareholders?

The patent application describes potential use in multiple chronic gastrointestinal disorders. According to FibroBiologics, these include inflammatory bowel disease, irritable bowel syndrome, peptic ulcer disease, celiac disease, gastritis, Crohn's disease, ulcerative colitis, and gastrointestinal cancers, reflecting a broad range of possible GI disease settings.

What types of fibroblast-derived therapeutics are included in FibroBiologics' new patent application (FBLG)?

The filing covers a wide array of fibroblast-based modalities for oral delivery. According to FibroBiologics, this includes whole fibroblast cells, spheroids, extracellular vesicles, fragments, conditioned media, and genetically modified variants designed for regenerative and immunomodulatory activity in the gastrointestinal tract.

Why does FibroBiologics consider the oral fibroblast platform important for future treatments (Nasdaq:FBLG)?

Management highlights oral fibroblast therapeutics as a potential non-invasive treatment approach. According to FibroBiologics, the platform may offer a way to deliver regenerative and immunomodulatory activity directly to the GI tract, supporting barrier function, inflammation modulation, and tissue repair in gastrointestinal disease contexts.

What is a provisional patent and what does FibroBiologics' filing imply for FBLG investors?

A provisional patent secures an early filing date while claims are refined. According to FibroBiologics, this provisional application seeks protection for a broad oral fibroblast therapeutic architecture, signaling continued IP expansion but without disclosed timelines for commercialization or clinical validation in this announcement.